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Prosthetic valve thrombosis (PVT) is a complication that
endangers the life of patients with prosthetic heart valves.
The incidence of PVT can be as high as 13% during the ﬁrst year
in any valve position and even 20% for mechanical prostheses
in the tricuspid position. At any time, for prostheses in the
mitral and/or aortic position, the overall incidence is 0.5–6%
per patient-year, the highest in the mitral position. The risk of
a thrombus, in spite of adequate oral anticoagulation, has been
estimated at between 1% and 4% per year. The prevalence of
asymptomatic nonobstructive PVT is 50%. During the early
postoperative period, nonobstructive PVT may reach 10%.1
It is mandatory that the antithrombotic prophylaxis in
these patients achieves an INR range of 2–4 as recommended
by guidelines regardless of thrombogenic risk factors.2
PVT is classiﬁed as obstructive if there is a limitation of the
leaﬂet mobility and a thrombus is present, clinically charac-
terized by progressive heart failure, pulmonary edema or
cardiogenic shock, and/or systemic embolism. In relation with
auscultation, occluder clicks are typically mufﬂed or absent.
Also, stenotic or regurgitant murmurs may be heard.
PVT is not obstructive when there is a thrombus but normal
mobility of the leaﬂet, and this may not only cause stroke or
peripheral embolism, but may also remain asymptomatic in
about 50% of cases.
Patient-related risk factors for PVT are: inadequate antic-
oagulation, left ventricular dysfunction, atrial ﬁbrillation,
pregnancy (hypercoagulability status), infection, early post-
operative period, and spontaneous echocontrast as diagnosed
by transoesophageal echocardiography (TEE).§ This editorial is pertaining to the article: Successful use of Tene
thrombosis.2. Diagnosis
A high degree of clinical suspicion will lead to the diagnosis of
PVT. The clinical history and cardiac auscultation are often
suggestive. Compliance with an adequate anticoagulant
therapy should be veriﬁed, including the INR values in
preceding weeks, since sub-therapeutic levels are important
diagnostic clues. The patient and/or relatives may report
disappearance or attenuation of the prosthetic noise, which
should be conﬁrmed by auscultation. The latter may reveal a
previously nonexistent murmur.
Imaging techniques are basic tools in diagnosing PVT.
Fluoroscopy and cardiac computed tomography can help to
detect alterations in the movement of the prosthetic leaﬂets,
such as variations in the opening and closure angles.
Transthoracic echocardiography (TTE) is indicated to
patients with suspected PVT in order to assess hemodynamic
severity and follow resolution of valve dysfunction.
TEE is the best diagnostic tool to evaluate the mobility of the
valve and the thrombus size. Itmay also be useful to differentiate
thrombus from pannus as the mechanism of prosthetic
obstruction. Thrombus is larger, more mobile, and lower in
density than pannus. Thrombus size is an important indepen-
dent predictor of lack of success of thrombolysis in the PVT.
Real-time 3-dimensional (3D) TEE provides a live ‘‘en face’’
surgical view of the mitral valve, which can improve diagnostic
accuracy for detecting mitral prosthetic valve pathologies.
Real-time 3D TEE can detect prosthetic mitral thrombosis that
could be missed on a 2D TEE and cause thromboembolic
events.3cteplase in a patient with recurrence of prosthetic mitral valve
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PVT can be treated with three therapeutic modalities: surgery,
thrombolysis, and anticoagulation. Surgery has been tradi-
tionally the ﬁrst choice therapeutic for PVT (prosthetic valve
replacement or thrombectomy).
The evidence supporting the guidelines on PVT is scarce and
recommendations from various organizations are not uniform.4
The European Society of Cardiology proposes surgery as the
initial treatment, regardless of clinical status and the size of the
thrombus. The Society of Heart Valve Disease recommends that
the ﬁrst choice should be thrombolysis in all cases of PVT, unless
such treatment is contraindicated. The American Heart
Association and American College of Cardiology reserves
thrombolysis only for patients with PVT of recent onset (<14
days) of New York Heart Association (NYHA) functional class I to
II symptoms, and for a small thrombus (<0.8 cm2). The
American College of Chest Physicians recommends that the
main criterion in the therapeutic decision should be the size of a
thrombus. The American College of Chest Physicians indicates
thrombolysis as the treatment choice if the thrombus has an
area of 0.8 cm2 and surgery in cases of older thrombi.
Despite advances in surgical techniques, anesthetics, and
perioperative care, surgical mortality rates are main high,
especially in patients with PVT and NYHA functional class III–IV.
Durrleman and coworkers presented a series of 39 patients
with PVT over a 20-year period who underwent thrombectomy
or valve replacement, with an associated mortality of 25% and
41%, respectively. Oskokeli et al. in 30 patients with left-side
PVT, reported a postoperative early hospital mortality of 7.1%
(NYHA classes II–III) and 31.3% (NYHA IV) and Toker et al.
reported in 63 cases a total mortality of 20.6%. Keuleers
reported a mortality rate of 11% in 18 patients with PTV treated
with emergency surgery. Ermis obtained 16.6% surgical
mortality in 18 patients with PVT.
The effective implementation of thrombolysis in PVT in
1971, by Luluaga5 started the debate in determining the ﬁrst
therapeutic option for these patients, i.e. surgery or throm-
bolysis, for which the debate has not ended.
In this issue of Indian Heart Journal, Lahoti and Goyal publish
a manuscript entitled ‘‘Thrombolytic therapy for left side
prosthetic valve thrombosis: Short and long term follow up
study.6 In this article, they report a series of 11 patients with a
diagnosis of PVT who received thrombolytic therapy with
streptokinase. They were evaluated at 24 h, 72 h, and the 7thTable 1 – Indian series of patients with PVT and thrombolytic 
Study (First Author, Journal, Year of publication) Enrolment 
Vasan (Am Heart J 1992) 1990–19
Reddy (Ann Thorac Surg 1994) 1990–19
Rajasekhar (Indian Heart J 1994) 1992–19
Agrawal (Indian Heart J 1997) 1987–19
Gupta (Am Heart J 2000) 1990–19
Kumar (Indian Heart J 2001) 1994–20
Karthikeyan (Circulation 2009) 2004–20
Sharma (J Assoc Phys India 2012) – 
Lahoti and Goyal (Indian Heart J 2015) – 
Total 1990–20day after the intervention. Long-term follow-up was extended
by seeing the patients every 3–6 months. The treatment was
successful in 8 patients (73%), whereas three patients died,
who had presented with functional class NYHA IV with
hypotension and cardiogenic shock. It seems unlikely that the
alternative, surgical treatment would have proven successful
in these seriously ill patients. The authors report no
complications of the thrombolytic therapy reported. During
extended follow-up, survival was between 1 and 10 years with
an average of 5 years up to the present.
In India, PVT occurrence is high, with 6.1% in the ﬁrst
6 months after replacement of the valve. While thrombolysis
has been gaining ground universally, the limitedavailability and
high cost of surgery have turned ﬁbrinolytic therapy into the
ﬁrst line therapy for PVT in most developing countries. Between
1990 and 2015, several series of cases with diagnostics PVT
treated with thrombolysis have been published, with a total
number of patients reported on is of 413 with an acceptable
initial success rate of 81.1% (Table 1). The risk of systemic
embolism, bleeding, and recurrence are crucial parameters that
form part of the recommendations of the latest guidelines.
Favorably, thrombolysis has a high rate of success in patients
with hemodynamic instability. If partial clot lysis can be
achieved by thrombolysis, this may still be useful, for patients
can then undergo surgery with improved hemodynamic
conditions and thus at lower risk. Other arguments that favor
thrombolysis are its widespread availability, easy application,
and low cost in comparison withsurgery.7
4. Recent evidence
In an attempt to clarify the best therapy treating PVT, several
meta-analyses and systematic reviews have been published in
recent years.
Karthikeyan and colleagues8 compared emergency surgery
with ﬁbrinolysis in left-sided prosthetic heart valve thrombo-
sis. This overview included seven studies with 690 episodes of
PVT, 446 treated with surgery, and 244 with thrombolysis. The
primary outcome variable was the restoration of valve
functions. The authors found no clear differences in the main
outcome between patients treated surgically (446) of whom
60 died (13.5%) and 244 patients treated with thrombolysis, of
whom 22 died (9%). Despite these results suggesting the
contrary, the study concluded that in experienced centers,
urgent surgery should probably be preferred over thrombolysistherapy (years 1990–2015).
period Thrombolysis samples size Efﬁcacy rate (n/%)
91 16 16/100
93 44 39/88.6
93 13 12/92
97 42 37/88
99 110 101/91.8
00 48 42/87.5
07 119 70/59
10 10/100
11 8/72.7
15 413 335/81.1
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on a lower rate of thromboembolic events, major bleeding, and
recurrent PVT.
Huang and co-workers9 conducted a literature survey,
including 17 studies comprising 756 patients who had received
thrombolytic therapy and 13 studies comprising 662 patients
who had received surgery. The survey's results revealed 30-
day mortality in the group treated with surgery at 15% (98
deaths in 662 patients) vs. 8% (61 deaths in 756 patients) in the
thrombolysis pooled. The rates of recurrence and complica-
tions, however, were higher in patients treated with throm-
bolysis. On this basis, they recommended thrombolysis as a
ﬁrst choice for patients in NYHA Class I/II with severe co-
morbid conditions associated with a high surgical operative
mortality and if surgery is not available, the patient refuses
surgery or ‘‘small thrombus’’ – area < 0.8 cm2. Initially, surgery
may be the preferred therapy for patients in NYHA functional
Class III/IV and with a large thrombus (area ≥ 0.8 cm2).
In 2014, we published a meta-analysis and a systematic
review that included 48 studies with 10 or more patients.10
The total number of patients was 2239. Twenty-seven studies
or study arms were evaluated with 1132 patients in the
surgery cohort and 26 studies with 1107 patients were
included in the thrombolysis cohort. There was a highly
signiﬁcant difference in mortality between the two groups:
surgery, 18.1% (CI, 14.6–22.1%) and thrombolysis, 6.6% (CI, 4.8–
9.9%) (P < 0.001). A trend of mortality increment directly
associated with the proportion of patients in NYHA class IV
appeared in patients with surgical treatment. Subgroup
analysis revealed that mitral valve thrombosis showed
similar mortality to the general analysis: 6.5% (4.2–9.9%)
related to thrombolytic therapy (n = 307 in 14 studies) and
20.5% (14.9–27.7%) related to surgery (n = 196 in 11 studies)
(P < 0.001). Another subgroup analysis for left-side valve
thrombosis also had similar results: 6.5% (4.3–9.7%) related to
thrombolytic therapy (n = 345 in 14 studies) and 17.8% (14.1–
22.4%) related to surgery (n = 364 in 12 studies) (P < 0.001). The
incidence of a stroke was similar in both treatment groups:
surgery, 5.6% and thrombolysis, 4.3% (P = 0.29). As expected,
embolic events were more common in the thrombolysis group
(4.6% vs. 12.8%, P < 0.01). However, there was no statistical
difference in the bleeding rate (4.6% and 6.8%) or intracranial
hemorrhage (2.1% vs. 3.3%, P = 0.24).
Finding an answer to the therapeutic dilemma in random-
ized trials is unlikely due to the sample size that is required.
Based on our results, it would be necessary to recruit at least
1024 patients in each arm (2048 patients total) to evaluate the
combined endpoints of stroke and death in a randomized trial
with 80% power and 5% alpha error.
Even considering the possibility of a multicenter study, it
would be difﬁcult, if not impossible to achieve such sample
size. Another possible solution could be a large prospective
observational multicenter registry.
The outcome of this meta-analysis suggests a leading role
for thrombolytic treatment in patients with PVT.
Based on recent evidences and our personal experience, new
guidelines should incorporate thrombolysis as a ﬁrst choice
treatment in patients with left-side PVT with NYHA functional
class III–IV, because of the effectiveness, safety proﬁle, avail-
ability, simplicity, and low cost of thrombolysis.Surgery should be reserved for patients with speciﬁc
contraindications for thrombolysis in PVT (large left atrial
thrombus >5 mm ischemic stroke in the ﬁrst 4–6 weeks and
ﬁrst 4 days of perioperative period) or if thrombolysis fails.
Conﬂicts of interest
The authors have none to declare.
r e f e r e n c e s
1. Cáceres-Lóriga FM, Pérez-López H, Santos-Gracia J, Morlans-
Hernandez K. Prosthetic heart valve thrombosis: pathogenesis,
diagnosis and management. Int J Cardiol. 2006;110:1–6.
2. Nishimura RA, Otto CM, Bonow RO, et al. 2014 AHA/ACC
Guideline for the Management of Patients with Valvular
Heart Disease: A report of the American College of
Cardiology/American Heart Association Task Force on
Practice Guidelines. J Am Coll Cardiol. 2014;63:e57–e185.
3. Ozkan M, Gürsoy OM, Astarcıoğlu MA, et al. Real-time three-
dimensional transesophageal echocardiography in the
assessment of mechanical prosthetic mitral valve ring
thrombosis. Am J Cardiol. 2013;112:977–983.
4. Cáceres-Lóriga FM, Santos-Gracias J, Pérez-López H.
Thrombolysis versus reoperation in the management of
prosthetic valve thrombosis. Am J Cardiol. 2011;108:753.
5. Luluaga IT, Carrera D, D'Oliveira J, et al. Successful
thrombolytic therapy after acute tricuspid-valve
obstruction. Lancet. 1971;22:1067–1068.
6. Lahoti. Goyal. Thrombolytic therapy for left side prosthetic
valve thrombosis: short and long term follow up study.
Indian Heart J. 2015.
7. Lengyel M. Diagnosis and treatment of left-sided prosthetic
valve thrombosis. Expert Rev Cardiovasc Ther. 2008;6:85–93.
8. Karthikeyan G, Senguttuvan NB, Joseph J, Devasenapathy N,
Bahl VK, Airan B. Urgent surgery compared with ﬁbrinolytic
therapy for the treatment of left-sided prosthetic heart valve
thrombosis: a systematic review and meta-analysis of
observational studies. Eur Heart J. 2013;34:1557–1566.
9. Huang G, Schaff HV, Sundt TM, Rahimtoola SH. Treatment of
obstructive thrombosed prosthetic heart valve. J Am Coll
Cardiol. 2013;62:1731–1736.
10. Castilho FM, Sousa MR, Mendonca ALP, Ribeiro ALP,
Caceres-Loriga FM. Thrombolytic therapy or surgery for
valve prosthesis thrombosis: systematic review and
metaanalysis. J Thromb Haemost. 2014;12:1218–1228.
Fidel Manuel Cáceres-Lóriga MD, PhD*
University Central Hospital, Lubango, Angola
Humberto Morais MD
Principal Military Hospital/Superior Institute, Luanda, Angola
*Corresponding author
E-mail address: dr.caceres10@hotmail.com
(F.M. Cáceres-Lóriga)
Available online 21 November 2015
http://dx.doi.org/10.1016/j.ihj.2015.08.019
0019-4832/
# 2015 Cardiological Society of India. Published by Elsevier B.V.
All rights reserved.
